PatternsRadar
Sign in

MEDICAMEQMedicamen Biotech Limited

NSEESM 1Band 5%
285.90INR-1.50 (-0.52%)Close · 20 Nov 2026
13 Nov 2026Last results
—Sector
—Industry
₹402 CrMarket cap
34.7P/E (TTM)
100.0%Delivery

Filings & corporate actions

21 results filed
CSV
Next results · Q3 FY27
Expected 8 Feb 2027 – 13 Feb 2027
Estimate: filed 39–44 days after quarter end, last 5 times
Dividend
₹1.00 per share · last 18 Sept 2026
2026
  • 13 NovresultsResults · Q2 FY27 · consolidated and standalone+4.1%NSE
  • 27 OctshareholdingShareholding · 23 Oct 2026+0.3%NSE
  • 22 OctshareholdingShareholding · 30 Sept 2026+0.2%NSE
  • 18 SeptdividendDividend · ₹1.00 per share · record 19 Sept 2026-5.3%
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-8.6%NSE
  • 16 JulshareholdingShareholding · 30 Jun 2026+0.7%NSE
  • 27 MayresultsResults · Q4 FY26 · consolidated and standalone-4.6%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
  • 13 FebresultsResults · Q3 FY26 · consolidated and standalone-4.0%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-3.1%NSE

Reaction to results · all yearsrose on day 0 in 6 of 21 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2713 Nov 2026+4.1%——1.7×
Q1 FY2714 Aug 2026-8.6%-2.9%+32.3%4.3×
Q4 FY2627 May 2026-4.6%-13.7%-15.2%3.7×
Q3 FY2613 Feb 2026-4.0%-14.4%-23.5%1.2×
Q2 FY2614 Nov 2025-3.5%-2.3%-3.9%1.8×
Q1 FY2612 Aug 2025-3.7%+1.1%-4.1%1.3×
Q4 FY2530 May 2025-2.3%-1.5%-2.8%2.2×
Q3 FY2511 Feb 2025-2.0%+4.8%-8.9%2.2×
Q2 FY2515 Nov 2024+0.3%-2.0%+22.8%0.3×
Q1 FY2513 Aug 2024-4.3%+2.2%+9.2%1.7×
Q4 FY2429 May 2024-4.8%-4.6%-10.3%1.1×
Q3 FY2412 Feb 2024+8.3%+15.0%-16.7%13.7×
Q2 FY2410 Nov 20230.0%-1.2%-10.1%0.2×
Q1 FY248 Aug 2023+0.9%-6.1%-14.5%1.3×
Q4 FY2331 May 2023-3.3%-2.5%+3.2%1.5×
Q3 FY2310 Feb 2023-2.7%-7.3%-16.0%0.5×
Q2 FY2311 Nov 2022-4.8%-6.7%-8.2%0.9×
Q1 FY2310 Aug 2022-0.8%+13.2%+43.6%0.9×
Q4 FY2225 May 2022+2.2%+16.6%-3.6%1.3×
Q3 FY228 Feb 2022-7.2%-16.8%-21.7%3.0×
Q2 FY223 Nov 2021+16.0%+6.3%+16.4%—
Average-1.2%-1.1%-1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+16.2%
Profit YoY+27.9%
Interest cost YoY+9.0%
Revenue QoQ+14.5%
Profit QoQ+61.0%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+7.6%+9.6%+14.6%———
Profit+28.9%-4.0%-4.2%———

Key data

Open287.40
Day range277.30 – 291.00
52-week range212.40 – 447.65
From 52w high-36.1%
RSI (14)53.9
ATR (14)13.75
Volume4.9K
Avg volume (20D)12.4K
Rel volume0.40×
Volatility (1Y)47.6%
Turnover₹14.0L
Traded value (NSE)₹14.0L
VWAP283.66
SMA 50 / 200293.64 / 271.51
Price band5%

Delivery percentage

Latest · 20 Nov 2026100.0%
20-day avg100.0%
1-year avg66.4%
Percentile (own history)100th
Range11.9–100.0%
Sessions1,253

Over the last 20 sessions MEDICAMEQ settled 100.0% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 66.4%, so recent sessions are running 33.6 points higher than usual. That is the highest reading in the 1,253 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.35%
Dividend, trailing 12M₹1.00
Paid every year for5 yr
Shareholders11.7K · -0.2% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy973 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.52%+1.51%+7.83%+17.29%+7.14%-30.38%

Valuation

Market cap₹402 Cr
Market cap (NSE)₹388 Cr
Free-float cap₹231 Cr
P/E (TTM)34.7
P/E (NSE)38.8
EPS (TTM)8.23
P/B1.4
Net margin (TTM)5.5%
Other income / PBT21.0%
ROE4.2%
Debt / equity0.14
Shares outstanding1.36Cr
Listed—

Ownership

Promoter42.57%
Promoter Δ QoQ+2.11 pp
Public57.43%
FII4.35%
DII0.00%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)46.960.647.954.8
YoY chg+3.9%+104.8%+11.3%+16.2%
Net profit (₹ Cr)1.64.41.84.1
YoY chg-44.1%+138.6%+15.3%+94.8%
Net margin3.5%7.3%3.9%7.5%
EPS1.213.281.363.04

Shareholding over time

By quarter

23 Oct 2026 · promoter 42.57% · public 57.43%
30 Sept 2021: promoter 44.83%31 Dec 2021: promoter 43.60%31 Mar 2022: promoter 43.60%30 Jun 2022: promoter 43.60%12 Sept 2022: promoter 43.21%30 Sept 2022: promoter 43.21%31 Dec 2022: promoter 43.21%31 Mar 2023: promoter 43.21%30 Jun 2023: promoter 43.21%30 Sept 2023: promoter 43.21%31 Dec 2023: promoter 43.21%31 Mar 2024: promoter 43.21%30 Jun 2024: promoter 42.99%30 Sept 2024: promoter 42.99%31 Dec 2024: promoter 42.99%31 Mar 2025: promoter 43.16%24 Apr 2025: promoter 40.46%30 Jun 2025: promoter 40.46%30 Sept 2025: promoter 40.46%31 Dec 2025: promoter 40.46%31 Mar 2026: promoter 40.46%30 Jun 2026: promoter 40.46%30 Sept 2026: promoter 40.46%23 Oct 2026: promoter 42.57%
2021-092026-10
  • Promoter
  • Public and others
Promoter
42.57%
Public
57.43%
Promoter change
+2.11 pp
Filed
27 Oct 2026
FII
4.35%
DII
0.00%
Promoter pledged
0.00%

Who the public is

Mutual funds
0.00%

0.00 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
0.02%

+0.02 pp QoQ

Retail ≤ ₹2L
26.00%

-0.54 pp QoQ

HNI > ₹2L
6.02%

-0.59 pp QoQ

NRI
1.00%

-0.03 pp QoQ

Bodies corporate
2.00%

-0.07 pp QoQ

Shareholders
11,662

-0.2% QoQ

Major holders

As of 23 Oct 2026
HolderTypeHolding
SHIVALIK RASAYAN LIMITEDPromoter · Corporate42.57%
PHARMADANICA A/SCorporate9.53%
GINNERUP CAPITAL APSCorporate2.52%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRSOther1.21%
RAJESH MADANIndividual1.10%
VIJAY AMICHAND SANGHVIIndividual1.08%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 19 Sept 2022 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹1.00₹1.00
FY2025-261₹1.00₹1.00
FY2024-251₹1.00₹1.00
FY2023-241₹1.00₹1.00
FY2022-231₹1.00₹1.00
Ex-dateRecord dateDeclaredAdjusted
18 Sept 202619 Sept 2026₹1.00₹1.00
19 Sept 2025—₹1.00₹1.00
19 Sept 2024—₹1.00₹1.00
20 Sept 2023—₹1.00₹1.00
19 Sept 2022—₹1.00₹1.00

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
−₹1.1Cr
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
2.7 years ago
Disclosures on record
28
24 open-market of the newest 28
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
30 Sept 2026Sanjay BansalDirectorSell32.8K₹1.1Cr321.291.03L → 70.0K0.51%-0.24 pp7(2)told 30 Sept 2026
18 Sept 2024Geetika MadanOtherSell1.5K₹7.1L475.8631.5K → 30.0K0.23%-0.01 pp7(3)told 17 Sept 2024
18 Sept 2024Geetika MadanOtherSell1.0K₹4.0L398.2032.5K → 31.5K0.24%-0.01 pp7(3)told 17 Sept 2024
26 Mar 2024Geetika MadanOtherSell2.4K₹10.5L428.0736.9K → 34.5K0.27%-0.02 pp7(3)told 26 Mar 2024
23 Mar 2024Growel Remedies LimitedPromoterSell2.00L₹8.4Cr419.432.00L → —0.00%7(2)told 23 Mar 2024
23 Mar 2024Shivalik Rasayan limitedPromoterBuy2.00L₹8.5Cr424.3652.66L → 54.66L42.99%+1.57 pp7(2)told 23 Mar 2024
18 Mar 2024Geetika MadanOtherSell28.1K₹1.1Cr383.9765.0K → 36.9K0.29%-0.22 pp7(3)told 16 Mar 2024
8 Mar 2024Geetika MadanOtherSell5.5K₹25.6L462.5970.6K → 65.0K0.51%-0.04 pp7(3)told 8 Mar 2024
6 Mar 2024Geetika MadanOtherSell2.8K₹13.6L486.0173.4K → 70.6K0.56%-0.02 pp7(3)told 5 Mar 2024
2 Mar 2024Geetika MadanRelativeSell73.4K~₹3.6Cr486.7077.5K → 4.1K0.58%-10.33 pp7(2)told 1 Mar 2024
3 Jan 2022Growel Remedies LimitedPromoterSell25.0K₹2.3Cr904.952.25L → 2.00L1.64%-0.20 pp7(2)told 3 Feb 2022
31 Dec 2021Growel Remedies LimitedPromoterSell29.0K₹2.7Cr940.062.54L → 2.25L1.84%-0.24 pp7(2)told 31 Dec 2021
29 Dec 2021Growel Remedies LimitedPromoterSell46.0K₹4.5Cr987.713.00L → 2.54L2.08%-0.38 pp7(2)told 29 Dec 2021
21 Dec 2021Shivalik Rasayan LimitedPromoterBuy200₹1.5L758.3051.26L → 51.26L41.96%+0.00 pp7(2)told 21 Dec 2021
21 Dec 2021Growel Remedies LimitedPromoterSell1.6K₹12.9L815.373.02L → 3.00L2.46%-0.01 pp7(2)told 21 Dec 2021
18 Dec 2021Shivalik Rasayan LimitedPromoterBuy100₹77,690776.9051.26L → 51.26L41.96%+0.00 pp7(2)told 18 Dec 2021
18 Dec 2021Growel Remedies LimitedPromoterSell7.5K₹62.2L832.423.09L → 3.02L2.47%-0.06 pp7(2)told 18 Dec 2021
16 Dec 2021Shivalik Rasayan LimitedPromoterBuy7.1K₹51.3L723.5751.19L → 51.26L41.96%+0.06 pp7(2)told 16 Dec 2021
16 Dec 2021Growel Remedies LimitedPromoterSell23.5K₹1.9Cr793.233.33L → 3.09L2.53%-0.19 pp7(2)told 16 Dec 2021
15 Dec 2021Growel Remedies LimitedPromoterSell25.5K₹2.0Cr766.513.58L → 3.33L2.72%-0.21 pp7(2)told 13 Dec 2021
15 Dec 2021Shivalik Rasayan LimitedPromoterBuy10.2K₹77.4L757.1751.08L → 51.19L41.90%+0.08 pp7(2)told 13 Dec 2021
14 Dec 2021Growel Remedies LimitedPromoterSell20.5K₹2.0Cr953.473.58L → 3.38L2.76%-0.17 pp7(2)told 13 Dec 2021
10 Dec 2021Shivalik Rasayan LimitedPromoterBuy3.4K₹24.6L725.4151.05L → 51.08L41.82%+0.03 pp7(2)told 10 Dec 2021
10 Dec 2021Growel Remedies LimitedPromoterSell14.0K₹1.0Cr741.173.72L → 3.58L2.93%-0.11 pp7(2)told 9 Dec 2021

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Filings

CSV
Loading…

Bulk & block deals · 22 Mar 2024

CSV
2 of 2 deals
By year
DateDealClientQuantityPriceValue
22 Mar 2024Sell · bulkGROWEL REMEDIES LIMITED2.00L421.86₹8.4Cr
22 Mar 2024Buy · bulkSHIVALIK RASAYAN LIMITED2.00L421.86₹8.4Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.

Exchange surveillance

20 Nov 2026
  • ESM · stage 1 · since 17 Sept 2026 — Enhanced Surveillance Measure, for companies under ₹500 crore: a 5% or 2% price band and trade-for-trade settlement.

Price band: 5% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations46.547.343.044.745.129.643.047.246.960.647.954.8
Other income0.80.60.60.30.15.20.50.40.51.70.9(0.0)
Total income47.347.943.645.045.334.843.547.547.462.448.854.8
Total expenses44.145.242.143.141.432.441.444.945.357.346.249.7
└ Finance costs0.61.90.71.00.80.61.21.01.00.40.81.7
└ Depreciation1.81.81.82.62.20.51.81.91.81.71.81.9
Profit before tax3.32.71.62.03.92.52.12.72.15.12.65.1
Tax expense1.20.60.81.11.00.60.50.60.50.60.71.0
Net profit2.02.00.80.92.91.91.62.11.64.41.84.1
EPS1.601.610.630.712.301.471.181.561.213.281.363.04
Net margin4.37%4.31%1.86%2.02%6.47%6.29%3.72%4.48%3.48%7.33%3.85%7.51%
PBT margin7.04%5.61%3.62%4.37%8.59%8.41%4.95%5.69%4.50%8.34%5.37%9.34%
Tax rate37.97%23.17%48.68%53.80%24.63%25.16%24.89%21.19%22.56%12.11%28.22%19.56%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 13 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets278.5297.4294.5288.5296.9367.1372.0359.6
Current assets163.4175.5159.6156.8164.5223.4223.7206.3
└ Cash & equivalents20.813.414.86.43.843.731.334.8
└ Other bank balances0.00.00.00.00.00.02.70.0
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables65.374.855.356.668.977.681.868.8
└ Inventories45.156.359.460.062.168.870.163.4
Total equity193.4199.9200.5215.9212.8275.4275.6281.5
└ Attributable to owners193.4199.9200.5215.9212.8275.4275.6281.5
└ Share capital12.712.712.712.712.713.613.613.6
Borrowings24.229.030.820.233.338.647.840.7
└ Current23.327.129.618.829.535.041.633.1
└ Non-current0.91.91.31.43.73.66.27.6
Trade payables47.655.945.444.942.643.240.027.1
Current liabilities82.694.191.068.878.285.687.967.9
Total liabilities85.197.594.072.684.191.796.478.1
Net debt3.415.616.013.829.5(5.0)13.95.9
Debt / equity0.130.150.150.090.160.140.170.14
Current ratio1.981.871.752.282.112.612.543.04

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow(6.3)(7.6)(0.4)(8.5)(7.2)(12.4)(33.2)13.6
└ Capex(6.6)(3.9)(6.3)(1.2)(2.1)(2.2)(4.8)0.0
Free cash flow(12.9)(11.5)(6.7)(9.7)(9.3)(14.6)(38.0)13.6
Investing cash flow(5.9)(3.8)(5.6)(1.1)(1.9)(1.5)(3.0)(0.4)
Financing cash flow29.14.0(0.1)1.3(1.9)53.863.7(9.6)
└ Dividends paid(1.3)0.0(1.3)0.0(1.3)0.0(1.4)0.0
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash17.0(7.4)(6.0)(8.4)(11.0)39.927.53.5

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

MEDICAMEQ at a glance

  • MEDICAMEQ closed at ₹285.9 on 20 Nov 2026, -0.52% on the day, -30.4% over one year, 36.1% below its 52-week high of ₹447.65.
  • Delivery was 100.0% of traded quantity on 20 Nov 2026, the 100th percentile of its own 1,253 sessions with a reading (20-session average 100.0%, 1-year average 66.4%).
  • Market capitalisation is ₹402 crore at a trailing P/E of 34.7 (trailing EPS ₹8.23).
  • Q2 FY27 results (consolidated, filed 13 Nov 2026): revenue ₹55 crore (+16.2% year on year), net profit ₹4 crore (+94.8%); the price moved +4.1% on the first session after.
  • Promoters held 42.57% at 23 Oct 2026, up 2.11 percentage points on the previous filing.
  • Q3 FY27 results are expected between 8 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sector—
Basic industry—
ISININE646B01010
SeriesBE
Listed—
NSE market cap · 17 Nov 2026—
Free-float market cap (NSE)—
Shares outstanding (NSE)—
History from27 Oct 2021
Sessions1,257

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.